Braidwell »

Vyne Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2026-03-31 $547k 916k 0.60

More positions owned by Braidwell

Caris Life Sciences (CAI)
Guardant Health Debt 1.250% 2/1 (Principal)
Repligen Corp Note 1.000%12/1 (Principal)
Neogenomics Note 0.250% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Glaukos (GKOS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Xenon Pharmaceuticals (XENE)
Dianthus Therapeutics (DNTH)
Edgewise Therapeutics (EWTX)
Irhythm Technologies (IRTC)
Nuvalent Inc-a (NUVL)
Kodiak Sciences (KOD)
Cg Oncology (CGON)
Alphatec Hldgs Note 0.750% 3/1 (Principal)

View all positions for Braidwell

Top funds holding Vyne Therapeutics

Nantahala Capital Management
Lynx1 Capital Management
Shay Capital
Frigate Ventures
ADAR1 Capital Management
T3 Companies
Braidwell
Citadel Advisors
KVP Capital Advisors
Two Sigma Investments
Acadian Asset Management
Geode Capital Management
Vanguard Group
Ikarian Capital
Vanguard Capital Management

View all funds holding Vyne Therapeutics